Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Protests 'Incomprehensible' German Decision on Stivarga In mCRC

This article was originally published in Scrip

Executive Summary

A decision by the German health technology assessment agency IQWiG that new analysis provided by Bayer of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) result in the product's disadvantages outweighing its benefits "is essentially incomprehensible to Bayer," the German pharma told Scrip.


Related Content

Bayer Set To Sew Up HCC Market As RESORCE Hits Endpoint





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts